Therapeutic Drug Monitoring

Breakthrough technology to enhance monoclonal antibody-based treatment

Labelled Cetuximab 13C15N

Application

Absolute quantification of Erbitux or its biosimilars

Specific labelling

Arginine: 13C6,15N4, >99%

Lysine: 13C6,15N2, >99%

10 µg     ->    650 €      Quantity  

You must sign in or create an account to order this product

Description
Datasheet
Price

Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.